Continued positive safety data across a range of ICT01 doses in 69 cancer patients and updated efficacy data from 22 evaluable patients treated with ICT01 plus pembrolizumab
Clinical responses achieved with low doses of ICT01 in combination with pembrolizumab in solid tumor patients who previously failed checkpoint-inhibitor therapy support the complementary mechanisms of action with potential for anti-tumor activity in this difficult to treat patient population
Patient with checkpoint-inhibitor refractory metastatic melanoma achieved a complete response of a brain metastasis and a partial response of liver metastases with effects ongoing at 11 months
ImCheck Therapeutics provided newly updated patient response data from its ongoing EVICTION Phase I/IIa clinical trial of its lead candidate ICT01 in a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022. In efficacy evaluable patients (n=22) treated with the combination of low dose ICT01 plus pembrolizumab who previously failed at least one prior checkpoint inhibitor (CPI) regimen, 36% showed disease control by RECIST1.1 criteria. A previously reported metastatic melanoma patient with a brain metastasis, which would typically be unresponsive to standard of care treatments, achieved a complete response of the brain metastasis observed at week 27 of treatment with response ongoing at week 44.
“We continue to observe a robust safety and tolerability profile for ICT01 in the EVICTION trial while gaining important data on its immune remodeling activity on the tumor microenvironment in specific advanced solid tumor indications, which will inform the next stage of our development program,” commented Paul Frohna, MD, PhD, Chief Medical Officer at ImCheck Therapeutics.“The clinical results describing ICT01’s ability to induce activation and migration of circulating γ9δ2 T cells, CD8 T cells, and NK cells that leads to increased tumor infiltration by γδ, CD3 and CD8 T cells indicates it can safely coordinate broad anti-tumor immune responses in a group of patients who have previously failed multiple courses of therapy.”
Dr. Stéphane Champiat, EVICTION lead study investigator at the Gustave Roussy Cancer Center, Paris, France, will present the poster titled, “ICT01, an anti-butyrophilin 3A targeted mAb activating γ9δ2 T cells, induces immune remodeling of the tumor microenvironment and clinical responses in combination with pembrolizumab in patients with advanced solid tumors who failed prior checkpoint inhibitor therapy: EVICTION Trial”, on April 12, from 9:00am - 12:30pm CDT.
Pierre d’Epenoux, Chief Executive Officer of ImCheck Therapeutics added: “The positive results to date and the steady progress we have achieved with the EVICTION trial demonstrates the potential of ICT01 and ImCheck’s ability to execute an ambitious international study. We remain on target with our timelines and have started enrollment in the Phase 2a portion of the study with ICT01 as a monotherapy in patients with ovarian cancer or head and neck squamous cell cancer. Our goal is to further establish the therapeutic value and highly differentiated aspects of our approach.”
The poster will be made available on ImCheck’s website.